Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?

Toshiaki Iba, Jean Marie Connors, Alex C. Spyropoulos, Hideo Wada, Jerrold H. Levy

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Thromboembolic events contribute to morbidity and mortality in coronavirus disease 2019 (COVID-19). As a result, thromboprophylaxis using low-molecular-weight heparin (LMWH) is universally recommended for hospitalized patients based on multiple guidelines. However, ethnic differences with respect to thrombogenicity have been reported and the incidence of thromboembolic events is considered to be lower in the Asian population. Despite the importance of thromboprophylaxis, bleeding is also a side effect that should be considered. We examine the data relating to potential ethnic differences in thrombosis and bleeding in COVID-19. Although sufficient data is not yet available, current evidence does not oppose routine anticoagulant use and thromboprophylaxis using a standard dose of LMWH for admitted patients regardless of ethnicity based on our review.

Original languageEnglish
Pages (from-to)330-336
Number of pages7
JournalInternational Journal of Hematology
Issue number3
StatePublished - Mar 2021
Externally publishedYes


  • COVID-19
  • Deep vein thrombus
  • Ethnic difference
  • Thromboembolism
  • Thromboprophylaxis


Dive into the research topics of 'Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?'. Together they form a unique fingerprint.

Cite this